Balaji Amines Ltd

- Ongoing CAPEX of Rs. 750 crores for Balaji Specialty Chemicals (BSC) Unit II, split into two phases (Rs. 300-400 crores first phase, Rs. 350 crores second phase), targeting products like sodium cyanide, triethyl orthoformate, EDTA derivatives, and others. - Methylamines plant expansion of 40,000 tons capacity, expected to be commissioned by December 2024. - New plant for Electronic grade Dimethyl Carbonate (DMC) with 15,000 MT per annum capacity, targeting the India EV battery market, commissioning in FY24-25. - Dimethyl ether (DME) manufacturing project at Unit IV, expected launch by March 2025. - Proposed plants for N-Methyl Morpholine (3,000 TPA), N-(n-butyl) Thiophosphoric Triamide (NBPT, 2,500 TPA), and isopropylamine (modification of existing Ethylamine plant). - New 20 MW solar power plant at Solapur, Maharashtra; phase 1 with 8 MW expected operational by December 2024, aiming for up to 100% power from solar post expansions. - Hotel expansion with 40 additional rooms costing Rs. 30-35 crores.

- The company anticipates significant growth and favorable market conditions in FY 2024-25. - Standalone volume growth is guided at a minimum of 10% conservatively, excluding expansions. - Demand improvement observed with 8.25% volume growth year-on-year; expected to continue improving in coming quarters. - Capacity expansions (e.g., methylamine plant, specialty chemicals unit) will support volume and revenue growth. - New phases of CAPEX (total ~Rs. 750 crores) aimed at specialty chemicals expected to increase revenues substantially. - Solar power plant and captive power initiatives will improve cost efficiency and sustainability. - Specialty chemicals volume recovery is expected alongside sustained demand in amines and derivatives. - Improved utilization of DMF and methylamine plants will boost production and exports. - FY 2024-25 outlook is optimistic, targeting sustained revenue and volume growth backed by new capacities and market recovery.

- Management anticipates minimum standalone volume growth of 10% for FY '25, conservatively. - EBITDA margins are expected to range between 21% to 24% going forward. - Specialty Chemicals and amines derivatives expansions (e.g., new methylamine and dimethyl ether plants) should bolster growth. - New product launches and capacity expansions (e.g., BSC Unit II with Rs. 750 crore CAPEX) are set to drive incremental revenues, estimated to cross INR 1,000 crores from Unit II alone. - Increased captive consumption through expansions (e.g., methylamines) will improve margins and profitability. - Solar power plant commissioning by year-end aims to reduce power costs and carbon footprint, aiding cost-efficient operations. - The company remains debt-free, enabling financial stability for sustainable growth. - Overall, management expresses confidence in sustained growth, improved margins, and higher EPS buoyed by capacity additions and favorable market conditions.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Balaji Amines Limited. However, some relevant insights include: - The company foresees a period marked by significant growth and favorable market conditions in FY 2024-25. - Volume growth guidance is a minimum of 10% on a standalone basis, indicating healthy demand outlook. - Expansion plans such as the new methylamine plant commissioning in December 2024 and specialty chemicals capacity addition suggest anticipated orders. - Investment of Rs. 750 crores in subsidiary (BSC Unit II) with expected minimum Rs. 1,000 crores revenue from the new unit implies a strong order pipeline. - Solar power plant and captive power initiatives will support operational efficiencies underlying growth in orders. - Management expressed optimism regarding promising market opportunities and sustained growth. No precise quantitative or formal order book data was disclosed in the call transcript.

- For the Rs. 750 crores CAPEX on the BSC Unit II expansion: - The first phase (Rs. 300-400 crores) will be funded 99% through internal accruals. - For the second phase, depending on first phase operations, the company may need Rs. 50-100 crores debt borrowing. - Regarding IPO plans: - No specific updates were provided other than that the company had planned an IPO earlier. - Overall, no immediate large-scale equity fundraising mentioned; minor debt could be used for the second CAPEX phase.